By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Allergan (AGN) And Adamas Pharmaceuticals (ADMS) Announce New Expanded Indication For NAMZARIC (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease 7/19/2016 6:27:57 AM
Adamas Pharmaceuticals (ADMS) Announces Data Update At The 68th American Academy of Neurology Annual Meeting 4/15/2016 7:59:01 AM
Adamas Pharmaceuticals (ADMS) Provides Review Of 2015 And Projected Future Milestones 1/13/2016 7:24:16 AM
Adamas Pharmaceuticals (ADMS)' Lead Drug ADS-5102 Meets Phase III Goals; Stock Surges 12/23/2015 6:33:04 AM
Adamas Pharmaceuticals (ADMS) Reports Third Quarter 2015 Financial Results 11/13/2015 8:23:37 AM
Adamas Pharmaceuticals (ADMS) To Present At The 24th Annual Credit Suisse Healthcare Conference 10/27/2015 2:23:02 PM
Adamas Pharmaceuticals (ADMS) Reports Second Quarter 2015 Financial Results 8/12/2015 11:16:17 AM
Adamas Pharmaceuticals (ADMS) Completes Recruitment Of Its Phase III EASE LID Study Evaluating ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 7/10/2015 6:53:27 AM
Adamas Pharmaceuticals (ADMS) Issued U.S. Patent Relating To ADS-5102 Program 7/8/2015 7:16:47 AM
Adamas Pharmaceuticals (ADMS) To Present At The Cantor Fitzgerald InauguralHealthcare Conference 6/25/2015 12:04:59 PM
123456
//-->